PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/70 // (A61K 31/70, 31:47)

A1

(11) International Publication Number: WO 99/48503

(43) International Publication Date: 30 September 1999 (30.09.99)

(21) International Application Number: PCT/EP99/01897

(22) International Filing Date: 19 March 1999 (19.03.99)

(30) Priority Data:
9806324.1 24 March 1998 (24.03.98) GB

(71) Applicant *(for all designated States except US)*: PHARMACIA & UPJOHN S.P.A. [IT/IT]; Via Robert Koch, 1.2, I-20152 Milano (IT).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: GERONI, Cristina [IT/IT]; Via Correggio, 48, I-20149 Milan (IT). RIPAMONTI, Marina [IT/IT]; V.le Fulvio Testi, 91, I-20162 Milan (IT). CARUSO, Michele [IT/IT]; Via Desiderio, 3, I-20131 Milan (IT). SUARATO, Antonino [IT/IT]; Via Degli Imbriani, 39, I-20158 Milan (IT).

(81) Designated States: AU, BG, BR, CA, CN, CZ, HU, ID, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, US, YU, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ANTITUMOR COMPOSITION CONTAINING A SYNERGISTIC COMBINATION OF AN ANTHRACYCLINE DERIVATIVE WITH A CAMPTOTHECIN DERIVATE

(57) Abstract

There are provided the combined use of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin or 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin and an antineoplastic topoisomerase I inhibitor in the treatment of tumors and the use of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin in the treatment of brain tumors.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

ANTITUMOR COMPOSITION CONTAINING A SYNERGISTIC COMBINATION OF AN ANTHRACYCLINE DERIVATIVE WITH A CAMPTOTHECIN DERIVATE

The present invention relates in general to the field of cancer treatment and, more particularly, provides an antitumor composition comprising an alkylating anthracycline and a topoisomerase I inhibitor, having a synergetic antineoplastic effect.

The present invention provides, in a first aspect, a pharmaceutical composition for use in antineoplastic therapy in mammals, including humans, comprising

- an anthracycline of formula Ia or Ib :



Ia



Ib

- an antineoplastic topoisomerase I inhibitor, and a pharmaceutically acceptable carrier or excipient.

The chemical names of the anthracyclines of formula Ia and Ib are 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methansulfonyl daunorubicin (Ia) and 4-demethoxy-N,N-bis(2-chloroethyl)-4'-methansulfonyl daunorubicin (Ib). These anthracyclines were described in Anticancer Drug Design (1995), vol. 10, 641-653, and claimed respectively in US-A-5,532,218 and US-A-5,496,800. Both compounds intercalate into DNA via the chromophore and alkylate guanine at N^7 position in DNA minor groove via their reactive moiety on position 3' of the amino sugar. Compounds

Ia and Ib are able to circumvent the resistance to all major classes of cytotoxics, indicating that the compounds represent a new class of alkylating drugs.

Topoisomerase I inhibitor are described in various scientific publications, see for example the review of M.L. Rothenberg, "Topoisomerase I inhibitors: Review and update", Annals of Oncology, 8: 837-855, 1997.

Typically, a topoisomerase I inhibitor is camptothecin or its derivative substituted on the quinoline ring or at position 20-OH. Examples of specific topoisomerase I inhibitor to be used in the present invention are: camptothecin, 9-aminocamptothecin, irinotecan (CPT-11), topotecan, 7-ethyl-10-hydroxy-camptothecin, GI 147211 and 9-nitrocamptothecin. All these camptothecin derivatives are known, see for example Medicinal Research Reviws, Vol 17, n° 4, 367-425, 1997. Irinotecan (CPT-11) is the preferred topoisomerase I inhibitor to be used in the present invention. The present invention also provides a product comprising an anthracycline of formula Ia or Ib as defined above and an antineoplastic topoisomerase I inhibitor, as combined preparation for simultaneous, separate or sequential use in antitumor therapy.

A further aspect of the present invention is to provide a method of treating a mammal including humans, suffering from a neoplastic disease state comprising administering to said mammal an anthracycline of formula Ia or Ib as defined above and an antineoplastic topoisomerase I inhibitor, in amounts effective to produce a synergetic antineoplastic effect.

The present invention also provides a method for lowering the side effects caused by antineoplastic therapy with an antineoplastic agent in mammals, including humans, in need thereof, the method comprising administering to said mammal a

combination preparation comprising an antineoplastic topoisomerase I inhibitor as defined above and an anthracycline of formula Ia or Ib, as defined above, in amounts effective to produce a synergetic antineoplastic effect.

By the term "a synergetic antineoplastic effect" as used hererin is meant the inhibition of the growth tumor, preferably the complete regression of the tumor, administering an effective amount of the combination of an anthracycline of formula Ia or Ib as defined above and a topoisomerase I inhibitor to mammals, including human.

By the term "administered " or "administering" as used herein is meant parenteral and /or oral administration. By "parenteral" is meant intravenous, subcutaneus and intramuscolar administration. In the method of the subject invention, the anthracycline may be administered simultaneously with the compound with the topoisomerase I inhibitor activity, for example of the camptothecin analog class, or the compounds may be administered sequentially, in either order. It will be appreciated that the actual preferred method and order of administration will vary according to, inter alia, the particular formulation of the anthracycline of formula Ia or Ib being utilized, the particular formulation of the topoisomerase I inhibitor, such as one of the camptothecin analog class, being utilized, the particular tumor model being treated, and the particular host being treated .

In the method of the subject invention, for the administration of the anthracycline of formula Ia or Ib, the course of therapy generally employed is from about 0.1 to about 200 mg/m^2 of body surface area. More preferably, the course

therapy employed is from about 1 to about 50 mg/m^2 of body surface area.

In the method of the subject invention, for the administration of the topoisomerase I inhibitor the course of therapy generally employed is from about 1 to about 1000 mg/m^2 of body surface area for about one to about five consecutive days. More preferably, the course therapy employed is from about 100 to about 500 mg/m^2 of body surface area per day for about five consecutive days.

The antineoplastic therapy of the present invention is in particular suitable for treating breast, ovary lung, colon, kidney and brain tumors in mammals, including humans.

In a further aspect, the present invention is directed to the preparation of a pharmaceutical composition contaning an effective amount of an anthracycline of formula Ia for the treatment of brain tumors, as well as to the use of an anthracycline of formula Ia for the treatment of brain tumors. As a matter of fact, the anthracycline of formula Ia crosses the blood brain barrier and showed activity against intracranially implanted tumors.

As stated above, the effect of an anthracycline of formula Ia or Ib and a topoisomerase I inhibitor, such as camptothecin derivative, is significantly increased without a parallel increased toxicity. In other words, the combined therapy of the present invention enhances the antitumoral effects of the alkylating anthracycline and of the topoisomerase I inhibitor and thus yields the most effective and least toxic treatment for tumors. The superadditive actions of the combination preparation of the present invention are shown for instance by the following *in vivo* tests, which are intended to illustrate but not to limit the present invention.

Table 1 shows the antileukemic activity on disseminated L1210 murine leukemia obtained combining Ia with CPT-11. At the dose of 20 mg/kg of CPT-11 alone (days +1,2) and at the doses of 2.9 and 3.8 mg/kg of Ia alone (day +3) were associated, without toxicity, with ILS% values of 100, 92 and 108, respectively; combining CPT-11 and Ia at the same doses of 2.9 with the same schedule an increase of activity with ILS% values of 375 (with 3/10 cured mice) and >950 (with 8/10 cured mice) was observed, indicating a synergistic effect.

For these experiments Ia was solubilized in [Cremophor® /EtOH= 6.5:3.5]/[normal saline]=20/80 v/v, while CPT-11 was solubilized in water.

Activity against brain implanted tumor model

Brain tumors/metastases are generally unresponsive largely because cytotoxic drugs fail to cross the blood brain barrier. Since data showed that the anthracycline of formula Ia crosses the blood brain barrier, the antitumor efficacy of the anthracycline of formula Ia was tested against intracranially implanted P388 tumor cells in mice. The compound was administered i.v. on days 1,5,9. Results reported in Tab. 2 show that the anthracycline of formula Ia presented good antitumor activity as expressed by ILS% value of 46 at the optimal cumulative dose of 8.1 mg/kg.

Table 1: Antileukemic activity against disseminated L1210[1] of Ia in combination with CPT-11

Compound	Treatment schedule	Dose[2] (mg/kg/day)	ILS%[3]	Tox[4]	LTS[5]
CPT-11	iv+1,2	20	100	0/10	1/10
Ia	iv+3	2.9 3.8	92 108	0/10 0/10	0/10 0/10
CPT-11 + Ia	iv+1,2 iv+3	20 2.9	375	0/10	3/10
CPT-11 + Ia	iv+1,2 iv+3	20 3.8	>950	0/10	8/10

1) L1210 leukemia cells (10^5/mouse) are injected iv on day 0.

2) Treatment is given iv starting on day 1 after tumor transplantation (day 0).

3) Increase in life span : [(median survival time of treated mice/median survival time of controls) x 100] -100.

4) Number of toxic deaths/number of mice.

5) Long Term Survivors (>60 days) at the end of the experiments.

Table 2 Activity against intracranially transplanted P388 murine leukemia[1]

Compound	Dose[2] (mg/kg/day)	ILS% [3]	Tox[4]
Ia	2.1	44	0/20
	2.7	46	1/20

1) P388 leukemia cells (10^4/mouse) injected intracranially on day 0.

2) Treatment is given i.v. on day 1,5,9 after tumor transplantation (day 0).Ia solubilized in Tween 80 at 10%

3) Increase in life span :[(median survival time of treated mice/median survival time of controls) x 100] -100.

4) Number of toxic deaths/number of mice.

Claims

1. Products containing an anthracycline of formula Ia or Ib:



Ia



Ib

and an antineoplastic topoisomerase I inhibitor as a combined preparation for simultaneous, separate or sequential use in the treatment of tumors.

2. Products according to claim 1 wherein the topoisomerase I inhibitor is camptothecin, 9-aminocamptothecin, irinotecan (CPT-11), topotecan, 7-ethyl-10-hydroxy-camptothecin, GI 147211 or 9-nitrocamptothecin

3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and, as active ingredient, an anthracycline of formula Ia or Ib as defined in claim 1 and an antineoplastic topoisomerase I inhibitor.

4. A composition according to claim 3 wherein the topoisomerase I inhibitor is camptothecin, 9-aminocamptothecin, irinotecan (CPT-11), topotecan, 7-ethyl-10-hydroxy-camptothecin, GI 147211 or 9-nitrocamptothecin

5. Use of an anthracycline of formula Ia or Ib as defined in claim 1 and an antineoplastic topoisomerase I inhibitor in the preparation of a medicament for use in the treatment of tumors.

6. Use according to claim 5 wherein the the topoisomerase I inhibitor is camptothecin, 9-aminocamptothecin, irinotecan (CPT-11), topotecan, 7-ethyl-10-hydroxy-camptothecin, GI 147211 or 9-nitrocamptothecin

7. Use of an anthracycline of formula Ia as defined in claim 1 in the preparation of a medicament for use in the treatment of brain tumors.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/01897

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/70 //(A61K31/70,31:47)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ZHANG, S. D. ET AL: "Inhibitory effects of homoharringtonine and hydroxycamptothecin in combination with other agents on cancer cell growth" ASIA PAC. J. PHARMACOL., 1992, 191-5, XP002112006 abstract page 195, line 3 - line 7 ---	1-6
Y	EDER JP ET AL: "Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo." CANCER CHEMOTHER PHARMACOL, 1998, 42 (4) P327-35, XP002112007 GERMANY * abstract; p.334 * --- -/--	1-6

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
12 August 1999	01/09/1999

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Uiber, P

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

In. .ational Application No
PCT/EP 99/01897

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category '	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 496 808 A (BARGIOTTI ALBERTO ET AL) 5 March 1996 (1996-03-05) cited in the application claims 1,2,29	1-7
Y	US 5 532 218 A (BARGIOTTI ALBERTO ET AL) 2 July 1996 (1996-07-02) cited in the application claims 1,6,10	1-7

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 99/01897

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5496808 A	05-03-1996	AT 134376 T	15-03-1996
		AU 661012 B	13-07-1995
		AU 2229492 A	11-02-1993
		CA 2112818 A	21-01-1993
		CN 1069981 A,B	17-03-1993
		CZ 9400024 A	13-07-1994
		DE 69208400 D	28-03-1996
		DE 69208400 T	27-06-1996
		DK 521458 T	18-03-1996
		WO 9301201 A	21-01-1993
		EP 0521458 A	07-01-1993
		FI 940011 A	03-01-1994
		GR 3019429 T	30-06-1996
		HK 1006460 A	26-02-1999
		HU 70480 A	30-10-1995
		IE 76921 B	05-11-1997
		IL 102409 A	08-12-1995
		JP 6508841 T	06-10-1994
		MX 9203928 A	01-04-1993
		NO 940026 A	16-02-1994
US 5532218 A	02-07-1996	AT 157369 T	15-09-1997
		AU 676625 B	13-03-1997
		AU 1066095 A	03-07-1995
		CA 2154890 A	22-06-1995
		CN 1117734 A,B	28-02-1996
		DE 69405214 D	02-10-1997
		DE 69405214 T	29-01-1998
		DK 683788 T	27-10-1997
		WO 9516695 A	22-06-1995
		EP 0683788 A	29-11-1995
		ES 2107294 T	16-11-1997
		FI 953784 A	09-08-1995
		GR 3025266 T	27-02-1998
		HU 73172 A	28-06-1996
		IL 111725 A	15-07-1998
		JP 8506835 T	23-07-1996
		NO 953163 A	02-10-1995
		NZ 276401 A	24-10-1997
		PL 310177 A	27-11-1995
		ZA 9409701 A	12-12-1995